Navigation Links
Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Date:11/3/2010

EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2). This study, which was previously presented at the 46th American Society of Clinical Oncology annual meeting, is the first prospective clinical trial of a drug to show treatment benefit in these patients.

Tuberous sclerosis is a genetic disorder that is estimated to affect 25,000 to 40,000 people in the US and may cause benign tumors to form in vital organs(3). SEGAs, benign brain tumors, occur in up to 20% of patients with TS and primarily affect children and adolescents(1,4,5). SEGAs may pose a significant medical risk, including the potential for swelling in the brain, or hydrocephalus(1).

According to data published in NEJM from this Phase I/II study of 28 patients conducted by Cincinnati Children's Hospital Medical Center, treatment with everolimus was associated with a significant reduction in primary SEGA volume at six months relative to baseline on independent central review (p<0.001). Seventy-five percent of patients (21 of 28) experienced a reduction of 30% or greater in the size of their largest SEGA and 32% (9 of 28) experienced a reduction of 50% or greater at six months relative to baseline(2).

The published study findings also showed that in nine of 16 patients, everolimus therapy was associated with a reduction from baseline to six months in overall frequency of seizures per 24 hour video electroencephalograms (EEG) (n=16; median change -1 seizure, p=0.022). Additionally, no patients required surgery or developed a new SEGA while receiving everolimus(2).

The most common adverse reactions observed (incidence greater than or equal to 30%) in this trial were mouth sores,
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 ... New Guide to that Market, its R&D and Sales Potentials ... assess the future of cancer-treating medicines? Visiongain,s new report gives ... stay ahead. There you discover financial data, R&D trends, opportunities, ... In our analysis you see forecasted sales to 2025 ...
(Date:9/3/2015)... 3,  2015 About Vision Care Products ... considered for this report are Rx lenses, frames, ... are primarily used by consumer for vision correction ... lenses and contact lenses require a prescription for ... cosmetic products that can be purchased like any ...
(Date:9/3/2015)... 3,  2015 About artificial organs ... which are implanted or integrated into individuals ... include artificial heart, kidney, pancreas, and cochlear ... polysulfone, and porous polypropylene), biologics, ceramics, and ... These organs are incorporated with different technologies ...
Breaking Medicine Technology:World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7Vision Care Market in the US 2015-2019 2Global Artificial Organ Market 2015-2019 2
... ZeaVision, LLC announced two internal promotions as the ... its leading EyePromise® nutraceutical products featuring ... to President effective immediately from his previous role of ... appointment to the ZeaVision Executive Board. Founder, ...
... Sept. 1 In recognition of September,s designation as ... Pain Physicians (ASIPP) today announced that it is planning ... life for the approximately 75 million Americans suffering from ... this outreach, ASIPP has developed a consumer section on ...
Cached Medicine Technology:Nutraceutical Leader Announces Internal Promotions of Key Personnel 2American Society of Interventional Pain Physicians (ASIPP) Promotes Patient Education and Outreach Initiatives During National Pain Awareness Month 2
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of ... the home is quite common. Mold can grow anywhere - on carpet, clothing, food, ... Checking for excessive moisture and water in the home is key to preventing mold ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient ... solution. , The patent-pending K Med Cups provide a quick and simple way to brew ... a cold, flu or cough. As a result, they enhance comfort and health. The invention ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Having access ... This has led to an increasing amount of unnecessary emergency room visits which affects ... and taxes the country’s health bill. Fortunately, a solution to alleviate this problem has ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance officers ... settlements under the Stark physician self-referral law. “Stark Law DOs and DON’Ts: ... Atlantic Information Services, Inc. (AIS), will detail which deals are attracting the most ...
(Date:9/4/2015)... GENEVA, IL (PRWEB) , ... September 04, 2015 , ... ... in Geneva, IL hosting Generation Rescue’s A Night of Hope event supporting families affected ... Ed French and Rowena and Joe Salas, joined together at the Oscar Swan Inn ...
Breaking Medicine News(10 mins):Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
... Dotinga HealthDay Reporter , WEDNESDAY, April 4 (HealthDay ... HIV vaccine failed to protect most people who received it, ... vaccine efforts. Scientists believe an HIV vaccine, designed to ... several years away. Tests of experimental vaccines have largely been ...
... criticized as having misogynistic messages and images. While more ... "brands" in recent years, critics argue that many of ... with regard to race, gender and sexuality in popular ... in the University of Missouri School of Journalism, and ...
... MA (April 4, 2012)-- IntegraGen, Inc., a biotechnology company ... of the ARISk Risk Assessment Test, a gender specific, ... associated with Autism Spectrum Disorder (ASD). The test is ... from multiplex familiessiblings of children with ASD who are ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... appears to lengthen the lives of patients with a ... a small phase 2 trial. The drug, belagenpumatucel-L ... cell lung cancer and increased the five-year survival rate ...
... cancer (IBC) is a very aggressive, often misunderstood type of ... with other types of breast cancer. The five-year survival rate ... rate for other types of breast cancer. The reason for ... often spreads quickly to other parts of the body, including ...
... (HealthDay News) -- ,People with metal-on-metal hip replacements do not ... years after they receive the device, according to a new ... researchers at the Universities of Bristol and Exeter in the ... Registry of England and Wales, which contains records on more ...
Cached Medicine News:Health News:From a Failed Vaccine, New Insights Into Fighting HIV 2Health News:Sexual objectification of female artists in music videos exists regardless of race, MU study finds 2Health News:IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children 2Health News:IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children 3Health News:Early Study Finds Some Promise for Lung Cancer Vaccine 2Health News:Researchers develop a new cell and animal model of inflammatory breast cancer 2Health News:Researchers develop a new cell and animal model of inflammatory breast cancer 3Health News:No Added Cancer Risk From Hip Replacement Materials: Study 2
... Reviews enable all those involved with healthcare ... the very latest evidence in their field ... harder each year as the volume of ... by delivering the best single source available ...
Treatment Strategies in Cardiovascular Medicine...
Pocket Medicine's Cardiology Bundle includes the following 4 applications: Treatment Strategies in Cardiovascular Medicine, Treatment Strategies in Interventional Cardiology, Treatment Strategies in ...
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
Medicine Products: